Nanotechnology-based Drug Delivery Market - By Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective), Global Forecast, 2023 - 2032

Nanotechnology-based Drug Delivery Market - By Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective), Global Forecast, 2023 - 2032

Nanotechnology-based Drug Delivery  Market Size

Nanotechnology-based Drug Delivery Market size accounted for USD 95.2 billion in 2022 and is estimated to grow at a CAGR of 12.6% to reach USD 308.4 billion by end of 2032. The growing preference for precision medicines is one of the significant growth drivers for the nanotechnology-based drug delivery industry.
 

As individuals have unique genetic makeup and varying responses to treatments, there is a rising demand for tailored therapeutic solutions. Therefore, nanotechnology-based drug delivery systems offer the ability to customize treatments based on specific patient characteristics. Also, by modifying nanoparticle properties, such as targeting ligands, size, and surface charge, personalized medicines can be developed to optimize treatment outcomes.
 

Nanotechnology-based drug delivery refers to the application of nanoscale materials and technologies in designing and developing systems for the targeted delivery of therapeutic agents, such as drugs, genes, or vaccines, to specific sites within the body.
 

COVID-19 Impact Analysis

The COVID-19 pandemic had a positive impact on the nanotechnology-based drug delivery market. The urgent requirement for effective treatments and vaccines against the virus has accelerated research and innovation in the field of drug delivery systems. Nanotechnology-based platforms have played a crucial role in the development of COVID-19 therapeutics by enabling targeted delivery, controlled release, and enhanced efficacy of antiviral drugs. For instance, according to a National Institute of Health (NIH) 2021 publication titled "Nanoparticles as an effective drug delivery system in COVID-19," nanomedicines and nano drug delivery systems have demonstrated effectiveness in treating COVID-19. As a result, the market showed a slight positive growth during pandemic. Furthermore, the pandemic has highlighted the importance of advanced drug delivery systems in responding to emerging infectious diseases. Hence, there was a growing demand for nanotechnology-based drug delivery solutions for COVID-19 and other infectious diseases.
 

Nanotechnology-based Drug Delivery Market Driving Factors

Nanotechnology in drug delivery market is experiencing a huge demand due to the surging prevalence of chronic diseases such as such as cancer, cardiovascular diseases, and neurological disorders. For instance, according to the Sudden Cardiac Arrest Foundation, in 2020, approximately 19.1 million deaths were attributed to CVD globally. The age-adjusted prevalence rate was 7354.1 per 100,000. Thus, nanotechnology-based drug delivery offers promising solutions to address the complexities of these diseases by delivering drugs with enhanced efficacy and reduced side effects. As a result, the demand for nanotechnology-based drug delivery systems is expected to surge, providing opportunities for businesses operating in this sector to develop innovative products and solutions to meet the growing healthcare demands.
 

Nanotechnology-based Drug Delivery Market Restraint

The development and implementation of nanotechnology-based drug delivery systems often involve advanced materials, complex manufacturing processes, and specialized expertise, that can lead to increased production costs. These elevated costs can pose challenges in terms of affordability and reimbursement, potentially limiting the widespread adoption of these innovative technologies. Thus, the high cost of nanotechnology-based drug delivery techniques will hamper the market share. Moreover, stringent regulatory policies will further restrict the market growth.
 

Nanotechnology-based Drug Delivery Market Analysis

Based on technology, the nanotechnology-based drug delivery market is segmented into nanocrystals, nanoparticles, liposomes, micelles, and other technologies. Nanoparticles dominated the global market in 2022 and will grow at 12.4% CAGR to reach USD 115.7 billion by the end of the forecast period. Continuous advancements in nanomaterials have led to the development of a diverse range of nanoparticle platforms, thereby offering flexibility and versatility in drug delivery applications. Furthermore, increasing investments from both public and private sectors, as well as collaborations between academia, industry, and research institutions, are driving the growth of nanotechnology-based drug delivery systems.
 

Based on application, the nanotechnology-based drug delivery market is segmented into neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, and other applications. The oncology segment accounted for 30.2% of the market share in 2022 and is projected to witness considerable growth over the analysis timeframe. Increasing prevalence of cancer is anticipated to accelerate the market growth. For instance, according to the American Cancer Society report, in 2023, more than 1.9 million new cancer cases and 609,360 cancer deaths are projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Therefore, adoption of nanotechnology-based drug delivery systems will allow for controlled and sustained release of anticancer drugs, ensuring optimal drug concentrations within the tumour over an extended period. This capability is crucial for combating cancer's complex nature and overcoming drug resistance thus, augmenting the market expansion.
 

North America nanotechnology-based drug delivery market accounted for 46.6% revenue share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. Factors such as increasing prevalence of chronic diseases, a high disposable income, and robust healthcare infrastructure is expected to supplement the regional growth. Also, favourable regulatory policies and initiatives in North America support the development and commercialization of nanotechnology-based drug delivery systems. Furthermore, presence of several leading pharmaceutical companies, research institutions, and academic centers that are actively involve in the research and development activities related to nanotechnology-based drug delivery systems is further expected to boost the regional market statistics.
 

Nanotechnology-based Drug Delivery Market Share

Major market players operating in the nanotechnology-based drug delivery market include

• AbbVie Inc.
• BlueWillow Biologics Inc.
• Camurus AB
• Celgene, Inc.
• Cristal Therapeutics
• EyePoint Pharmaceuticals
• Johnson

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Nanotechnology-based Drug Delivery Industry News

• In March 2020, Curadigm, an early-stage nanotechnology company announced the selection of its Nanoprimer technology by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization. The selection is based on the technology's potential to have a substantial impact on treatments across various disease indications, including cancer. This strategy helped the company to expand and grow.
   
• In May 2019, Nanobiotix launched Curadigm, a spinoff company that specialized in developing a nanotechnology platform for healthcare applications. This strategy emphasized Nanobiotix's commitment to innovate and explore the potential of nanotechnology in improving drug delivery and patient outcomes.
   

The nanotechnology-based drug delivery market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Technology

• Nanocrystals
• Nanoparticles
• Liposomes
• Micelles
• Other technologies

By Application

• Neurology
• Oncology
• Cardiovascular/Physiology
• Anti-inflammatory/Immunology
• Anti-infective
• Oher applications

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa